Download PDF
Thromb Haemost 2020; 120(01): 168-180
DOI: 10.1055/s-0039-3400299
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3

Alexander Akhmedov‡   *
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Fabrizio Montecucco‡   *
4   First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy
5   IRCCS Ospedale Policlinico San Martino Genoa–Italian Cardiovascular Network, Genoa, Italy
,
Sarah Costantino
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Daria Vdovenko
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Ariane Schaub Clerigué
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Daniel S. Gaul
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Fabienne Burger
6   Division of Cardiology, Foundation for Medical Researches, University of Geneva, Geneva, Switzerland
,
Aline Roth
6   Division of Cardiology, Foundation for Medical Researches, University of Geneva, Geneva, Switzerland
,
Federico Carbone
4   First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy
,
Luca Liberale 
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Mohammad Amrollahi-Sharifabadi
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
,
Valerio Gaetano Vellone
7   Division of Pathology, Department of Integrated Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy
8   Pathology Academic Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
,
Urs Eriksson
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
9   GZO Regional Health Center, Wetzikon, Switzerland
,
Christian M. Matter
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Lindsey A. Crowe
10   Division of Radiology, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
,
Jean-Paul Vallée
10   Division of Radiology, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
,
Francesco Paneni
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
Paul M. Vanhoutte
11   Department of Pharmacology, Hong Kong University, Hong Kong, Peoples Republic of China
,
Giovanni G. Camici
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
3   Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland
,
François Mach‡   *
6   Division of Cardiology, Foundation for Medical Researches, University of Geneva, Geneva, Switzerland
,
Thomas F. Lüscher   *
1   Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland
2   Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
12   Royal Brompton and Harefield Hospitals, Imperial College London, London, United Kingdom
› Author Affiliations Funding This research was funded by the Swiss National Science Foundation (Grant #310030–135815 to T.F.L.; Grant #310030–118245 to F.M.; Grant #32003B-134963/1 to F.M.; Grant #310030–1659 and #310030–165990 to C.M.M., and Grant #310030_175546 to G.G.C.), the Swiss Heart Foundation (to F.P.), the Holcim Stiftung (to S.C.), the Alfred and Annemarie von Sick Grants for Translational and Clinical Research Cardiology and Oncology (to G.G.C.), and the Foundation for Cardiovascular Research – Zurich Heart House (to A.A. and G.G.C.), Zurich, Switzerland. This work was supported in part by the Centre for Biomedical Imaging (CIBM) of EPFL, University of Geneva and the University Hospitals of Geneva and Lausanne, and the Swiss National Science Foundation for its financial support for the PRISMA MRI (R'Equip grants: SNF No. 326030–150816). G.G.C. and F.P. are the recipient of a Sheikh Khalifa's Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich. The study was supported by a grant from the Italian Cardiovascular Network of the Italian ministry of Health to F.M.
Further Information

Publication History

02 July 2019

18 September 2019

Publication Date:
13 December 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Ischemia/reperfusion (I/R) injury in acute myocardial infarction activates several deleterious molecular mechanisms. The transcription factor JunD regulates pathways involved in oxidative stress as well as in cellular proliferation, differentiation, and death. The present study investigated the potential role of JunD as a modulator of myocardial injury pathways in a mouse model of cardiac I/R injury. Infarct size, systemic and local inflammation, and production of reactive oxygen species, as well as cytosolic and mitochondrial apoptotic pathways were investigated in adult males after myocardial I/R. In wild-type (WT) mice, 30 minutes after ischemia and up to 24 hours following reperfusion, cardiac JunD messenger ribonucleic acid expression was reduced while JunB increased. Cardiac-specific JunD overexpressing mice (JunDTg/0 ) displayed larger infarcts compared with WT. However, postischemic inflammatory or oxidative responses did not differ. JunD overexpression reduced Sirt3 transcription by binding to its promoter, thus leading to mitochondrial dysfunction, myocardial cell death, and increased infarct size. On the other hand, JunD silencing reduced, while Sirt3 silencing increased infarct size. In human myocardial autopsy specimens, JunD-positive areas within the infarcted left ventricle staining corresponded to undetectable Sirt3 areas in consecutive sections of the same heart. Cardiac-specific JunD overexpression increases myocardial infarct size following I/R. These effects are mediated via Sirt3 transcriptional repression, mitochondrial swelling, and increased apoptosis, suggesting that JunD is a key regulator of myocardial I/R injury. The present data set the stage for further investigation of the potential role of Sirt3 activation as a novel target for the treatment of acute myocardial infarction.

Keywords

transcription factor - myocardial infarction - ischemia and reperfusion

* These authors contributed equally to this work.


Supplementary Material

 

  • References

  • 1 Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol 2017; 69 (15) 1952-1967
    PubMedGoogle Scholar
  • 2 Akhmedov A, Montecucco F, Braunersreuther V. , et al. Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. Eur Heart J 2015; 36 (08) 516-526
    CrossrefPubMedGoogle Scholar
  • 3 Cosentino F, Francia P, Camici GG, Pelicci PG, Lüscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol 2008; 28 (04) 622-628
    CrossrefPubMedGoogle Scholar
  • 4 Wu J, Xia S, Kalionis B, Wan W, Sun T. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int 2014; 2014: 615312
    PubMedGoogle Scholar
  • 5 Camici GG, Savarese G, Akhmedov A, Lüscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J 2015; 36 (48) 3392-3403
    CrossrefPubMedGoogle Scholar
  • 6 Costantino S, Paneni F, Cosentino F. Ageing, metabolism and cardiovascular disease. J Physiol 2016; 594 (08) 2061-2073
    CrossrefPubMedGoogle Scholar
  • 7 Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 2015; 36 (48) 3404-3412
    CrossrefPubMedGoogle Scholar
  • 8 Lu Y, Wang YD, Wang XY, Chen H, Cai ZJ, Xiang MX. SIRT3 in cardiovascular diseases: emerging roles and therapeutic implications. Int J Cardiol 2016; 220: 700-705
    CrossrefPubMedGoogle Scholar
  • 9 Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 2008; 28 (20) 6384-6401
    CrossrefPubMedGoogle Scholar
  • 10 Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol 2015; 309 (09) H1375-H1389
    CrossrefPubMedGoogle Scholar
  • 11 Paneni F, Osto E, Costantino S. , et al. Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation 2013; 127 (11) 1229-1240
    CrossrefPubMedGoogle Scholar
  • 12 Meixner A, Karreth F, Kenner L, Penninger JM, Wagner EF. Jun and JunD-dependent functions in cell proliferation and stress response. Cell Death Differ 2010; 17 (09) 1409-1419
    CrossrefPubMedGoogle Scholar
  • 13 Ricci R, Eriksson U, Oudit GY. , et al. Distinct functions of junD in cardiac hypertrophy and heart failure. Genes Dev 2005; 19 (02) 208-213
    CrossrefPubMedGoogle Scholar
  • 14 Paneni F, Costantino S, Kränkel N, Cosentino F, Lüscher TF. Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. Eur Heart J 2016; 37 (22) 1733-1737
    CrossrefPubMedGoogle Scholar
  • 15 Fernandez-Marcos PJ, Jeninga EH, Canto C. , et al. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep 2012; 2: 425
    CrossrefPubMedGoogle Scholar
  • 16 Ciarlo E, Heinonen T, Lugrin J. , et al. Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections. Sci Rep 2017; 7 (01) 3853
    CrossrefPubMedGoogle Scholar
  • 17 Carbone F, Crowe LA, Roth A. , et al. Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury. J Mol Cell Cardiol 2016; 94: 82-94
    CrossrefPubMedGoogle Scholar
  • 18 Crowe LA, Montecucco F, Carbone F. , et al. 4D cardiac imaging at clinical 3.0T provides accurate assessment of murine myocardial function and viability. Magn Reson Imaging 2017; 44: 46-54
    CrossrefPubMedGoogle Scholar
  • 19 Montecucco F, Bauer I, Braunersreuther V. , et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2013; 18 (06) 630-641
    CrossrefPubMedGoogle Scholar
  • 20 Helisalmi S, Vepsäläinen S, Hiltunen M. , et al. Genetic study between SIRT1, PPARD, PGC-1alpha genes and Alzheimer's disease. J Neurol 2008; 255 (05) 668-673
    CrossrefPubMedGoogle Scholar
  • 21 Nencioni A, da Silva RF, Fraga-Silva RA. , et al. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111 (02) 308-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Zernecke A, Bot I, Djalali-Talab Y. , et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102 (02) 209-217
    CrossrefPubMedGoogle Scholar
  • 23 Akhmedov A, Camici GG, Reiner MF. , et al. Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. Cardiovasc Res 2017; 113 (05) 498-507
    CrossrefPubMedGoogle Scholar
  • 24 Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res 2017; 113 (14) 1708-1718
    CrossrefPubMedGoogle Scholar
  • 25 Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol 2015; 78: 23-34
    CrossrefPubMedGoogle Scholar
  • 26 Parodi-Rullán RM, Chapa-Dubocq X, Rullán PJ, Jang S, Javadov S. High sensitivity of SIRT3 deficient hearts to ischemia-reperfusion is associated with mitochondrial abnormalities. Front Pharmacol 2017; 8: 275
    CrossrefPubMedGoogle Scholar
  • 27 Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K. Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 2008; 27 (35) 4757-4767
    CrossrefPubMedGoogle Scholar
  • 28 Laurent G, Solari F, Mateescu B. , et al. Oxidative stress contributes to aging by enhancing pancreatic angiogenesis and insulin signaling. Cell Metab 2008; 7 (02) 113-124
    CrossrefPubMedGoogle Scholar
  • 29 Gerald D, Berra E, Frapart YM. , et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004; 118 (06) 781-794
    CrossrefPubMedGoogle Scholar
  • 30 Tang X, Chen XF, Chen HZ, Liu DP. Mitochondrial Sirtuins in cardiometabolic diseases. Clin Sci (Lond) 2017; 131 (16) 2063-2078
    CrossrefPubMedGoogle Scholar
  • 31 Kim HS, Patel K, Muldoon-Jacobs K. , et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010; 17 (01) 41-52
    CrossrefPubMedGoogle Scholar
  • 32 Winnik S, Gaul DS, Preitner F. , et al. Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development. Basic Res Cardiol 2014; 109 (01) 399
    CrossrefPubMedGoogle Scholar
  • 33 Chen CJ, Fu YC, Yu W, Wang W. SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-κB. Biochem Biophys Res Commun 2013; 430 (02) 798-803
    CrossrefPubMedGoogle Scholar
  • 34 Samant SA, Zhang HJ, Hong Z. , et al. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol 2014; 34 (05) 807-819
    CrossrefPubMedGoogle Scholar
  • 35 Chen T, Li J, Liu J. , et al. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol 2015; 308 (05) H424-H434
    CrossrefPubMedGoogle Scholar
  • 36 Koentges C, Bode C, Bugger H. SIRT3 in cardiac physiology and disease. Front Cardiovasc Med 2016; 3: 38
    PubMedGoogle Scholar
  • 37 Gaul DS, Weber J, Van Tits LJ. , et al. Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. Cardiovasc Res 2018; 114 (08) 1178-1188
    CrossrefPubMedGoogle Scholar
  • 38 Koentges C, Pfeil K, Meyer-Steenbuck M. , et al. Preserved recovery of cardiac function following ischemia-reperfusion in mice lacking SIRT3. Can J Physiol Pharmacol 2016; 94 (01) 72-80
    CrossrefPubMedGoogle Scholar
  • 39 Braunersreuther V, Montecucco F, Asrih M. , et al. Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury. J Mol Cell Cardiol 2013; 64: 99-107
    CrossrefPubMedGoogle Scholar
  • 40 Inoue T, Ide T, Yamato M. , et al. Time-dependent changes of myocardial and systemic oxidative stress are dissociated after myocardial infarction. Free Radic Res 2009; 43 (01) 37-46
    CrossrefPubMedGoogle Scholar
  • 41 Shi JX, Wang QJ, Li H, Huang Q. SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis. Exp Ther Med 2017; 13 (01) 342-348
    CrossrefPubMedGoogle Scholar
  • 42 Wieringa WG, Lexis CP, Mahmoud KD. , et al. Time of symptom onset and value of myocardial blush and infarct size on prognosis in patients with ST-elevation myocardial infarction. Chronobiol Int 2014; 31 (06) 797-806
    CrossrefPubMedGoogle Scholar
  • 43 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 44 Stolfo D, Cinquetti M, Merlo M. , et al. ST-elevation myocardial infarction with reduced left ventricular ejection fraction: insights into persisting left ventricular dysfunction. A pPCI-registry analysis. Int J Cardiol 2016; 215: 340-345
    CrossrefPubMedGoogle Scholar
  • 45 Schloss MJ, Horckmans M, Guillamat-Prats R. , et al. 2-Arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction. Cardiovasc Res 2019; 115 (03) 602-613
    CrossrefPubMedGoogle Scholar
  • 46 Ray KK, Landmesser U, Leiter LA. , et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017; 376 (15) 1430-1440
    CrossrefPubMedGoogle Scholar